Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.58 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.47 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | CASP2 | P42575 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15452325 | 1.00 | SLC6A5 (0.58) | SLC6A5PAOXHDAC3HDAC1HDAC2 | |
| SCHEMBL9128874 | 0.94 | SLC6A5 (0.51) | SLC6A5PAOXHDAC3HDAC1HDAC2 | |
| SCHEMBL7209833 | 0.90 | SLC6A5 (0.67) | SLC6A5PAOXKDM4AHIF1ATET2 | |
| SCHEMBL7203302 | 0.90 | SLC6A5 (0.67) | SLC6A5PAOXKDM4AHIF1ATET2 | |
| SCHEMBL7208464 | 0.90 | SLC6A5 (0.67) | SLC6A5PAOXKDM4AHIF1ATET2 | |
| SCHEMBL7215984 | 0.90 | SLC6A5 (0.67) | SLC6A5PAOXKDM4AHIF1ATET2 | |
| SCHEMBL7215946 | 0.90 | SLC6A5 (0.67) | SLC6A5PAOXKDM4AHIF1ATET2 | |
| SCHEMBL12863577 | 0.90 | SLC6A5 (0.67) | SLC6A5PAOXKDM4AHIF1ATET2 | |
| SCHEMBL17373920 | 0.90 | SLC6A5 (0.67) | SLC6A5PAOXKDM4AHIF1ATET2 | |
| SCHEMBL8995394 | 0.90 | SLC6A5 (0.67) | SLC6A5PAOXKDM4AHIF1ATET2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3883926-B1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDE DERIVATIVES AND PROTEIN CONJUGATES THEREOF FOR USE AS LXR AGONISTS | REGENERON PHARMA (US) | 2024-07-10 | — | — | EP | disclosed |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-11786603-B2 | Optimized transglutaminase site-specific antibody conjugation | REGENERON PHARMACEUTICALS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| WO-2023129518-A1 | TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES | REGENERON PHARMACEUTICALS, INC. (US) | 2023-07-06 | — | — | WO | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | REGENERON PHARMACEUTICALS, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-04-14 | — | — | US | disclosed |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | ARARIS BIOTECH LTD (CH) | 2015-06-18 | — | — | US | disclosed |
| WO-2014202775-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2014-12-24 | — | — | WO | disclosed |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2014-12-04 | — | — | US | disclosed |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | ARARIS BIOTECH LTD (CH) | 2014-12-04 | — | — | US | disclosed |
| WO-2014140300-A1 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014072482-A1 | RECOGNITION TAGS FOR TGASE-MEDIATED CONJUGATION | INNATE PHARMA (FR) | 2014-05-15 | — | — | WO | disclosed |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | PAUL SCHERRER INSTITUT | 2013-07-25 | — | — | US | disclosed |
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | PAUL SCHERRER INSTITUT | 2013-07-25 | — | — | US | disclosed |
| WO-2013092998-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013092983-A2 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | INNATE PHARMA (FR) | 2013-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130189287-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | SLC6A5 4062/4885PAOX 899/4885HDAC3 2362/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | SLC6A5 4503/4885PAOX 728/4885HDAC3 1371/4885 |
| US-20220112158-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | SLC6A5 4391/4885PAOX 475/4885HDAC3 297/4885 |
| US-20140356385-A1 | ENZYMATIC CONJUGATION OF ANTIBODIES | DNPEP, MPO, FCGR3B | SLC6A5 3795/4885PAOX 876/4885HDAC3 1271/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | SLC6A5 3395/4885PAOX 3585/4885HDAC3 3355/4885 |
| US-11786603-B2 | Optimized transglutaminase site-specific antibody conjugation | TGM2, TGM3, TGM1 | SLC6A5 723/4885PAOX 2510/4885HDAC3 3157/4885 |
| US-20230035898-A1 | CYCLODEXTRIN PROTEIN DRUG CONJUGATES | SDCBP, DDOST, KRTCAP2 | SLC6A5 4491/4885PAOX 3268/4885HDAC3 2066/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | SLC6A5 3395/4885PAOX 3585/4885HDAC3 3355/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | SLC6A5 3851/4885PAOX 4125/4885HDAC3 1779/4885 |
| US-20150165064-A1 | ENZYMATIC CONJUGATION OF POLYPEPTIDES | DNPEP, ENPEP, PEPD | SLC6A5 4077/4885PAOX 814/4885HDAC3 2319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.